| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2801979801012 | 197980101 | SANDOSTATIN IN.SO.CR 0,1MG/ML AMP BTx5 AMP | 6.86 | 7.20 | 9.92 |
| 05/2018 | 2801979804013 | 197980401 | SANDOSTATIN IN.SO.CR 0,5MG/ML AMP BT x 5 AMP x 1ML | 68.90 | 72.28 | 91.95 |
| 05/2018 | 2802256704019 | 225670401 | SANDOSTATIN LAR PS.INJ.SUS 10MG/VIAL BTx 1 VIAL+ 1 PF.SYR x 2,5 ML SOLV + 2 βελόνες x 2,5 ML SOLV + 2 βελόνες | 361.81 | 367.23 | 428.19 |
| 05/2018 | 2802256705016 | 225670501 | SANDOSTATIN LAR PS.INJ.SUS 20MG/VIAL BTx1VIAL+1PF.SYR x 2,5 ML SOLV + 2 βελόνες x 2,5 ML SOLV + 2 βελόνες | 428.00 | 434.42 | 501.93 |
| 05/2018 | 2802256706013 | 225670601 | SANDOSTATIN LAR PS.INJ.SUS 30MG/VIAL BTx1VIAL+1PF.SYR x 2,5 ML SOLV + 2 βελόνες x 2,5 ML SOLV + 2 βελόνες | 643.08 | 652.73 | 740.33 |
For treatment of acromegaly and reduction of side effects from cancer chemotherapy
Octreotide binds to somatostatin receptors. These receptors are coupled via pertussis toxin sensitive G proteins which lead to inhibition of adenylyl cyclase. Octreotide binding to these receptors also stimulates phosphotyrosine phosphatase and activation of the Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins.
About 32% of the dose is excreted unchanged into the urine.
* 13.6 L [healthy volunteers] * 21.6±8.5 L [patients with acromegaly]
* 7 – 10 L/hr [healthy after 100-mcg SC injection] * 18 L/hr [patients with acromegaly after 100-mcg SC injection] * 8.8 L/hr [mild renal impairment after 100-mcg SC injection] * 7.3 L/hr [moderate renal impairment after 100-mcg SC injection] * 7.6 L/hr [severe renal impairment after 100-mcg SC injection] * 4.5 L/hr [severe renal failure requiring dialysis after 100-mcg SC injection] * 5.9 L/hr [Patients with liver cirrhosis after 100-mcg SC injection] * 8.2 L/hr [patients with fatty liver disease after 100-mcg SC injection]